Home ›
Leukemia Trials ›
NCT04741945
Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS
This is a single-arm pilot study of the feasibility and safety of metformin in patients with clonal cytopenia of undetermined significance (CCUS) or lower-risk myelodysplastic neoplasms (LR-MDS).
Trial Details
NCT ID NCT04741945
Phase PHASE2
Sponsor Kirsten Grønbæk
Status RECRUITING
Cancer Type Leukemia
Interventions
Locations (sample) Copenhagen, Copenhagen N, Denmark|55.67594,12.56553
Key Eligibility Criteria
A diagnosis of: LR-MDS according to the revised international prognostic scoring system (IPSS-R), i.e., very low- or low-risk disease (IPSS-R score ≤3) in addition… CCUS defined as the presence of somatic mutation(s) or cytogenetic abnormality not diagnostic of MDS or any other malignancy in the context of pers… Menopause, if being a female, defined as females \>45 years of age who have experienced amenorrhea for minimum 12 months, without any other obvious…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Leukemia Trials on Trialify →